Bèta-thalassemie major
Farmacologische inductie van de synthese van foetaal hemoglobine
Hydroxyureatherapie (hydroxycarbamidetherapie)
Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (opent nieuw venster)
Bron: J Pediatr Hematol Oncol 2011;33(5):339-43.
Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (opent nieuw venster)
Bron: Ann Hematol 2013;92(3):289-99.
Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (opent nieuw venster)
Bron: Transfusion 2007;47(10):1830-6.
Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (opent nieuw venster)
Bron: Blood 1996;87(3):887-92.
Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (opent nieuw venster)
Bron: Iran J Blood Cancer 2009;1(4):147-50.
Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (opent nieuw venster)
Bron: Hematology 2015;20(1):53-7.
Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (opent nieuw venster)
Bron: Int J Hematol 2012;95(1):51-6.
Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (opent nieuw venster)
Bron: Hemoglobin 2014;38(2):115-8.
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (opent nieuw venster)
Bron: Blood 2013;121(12):2199-212.
A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (opent nieuw venster)
Bron: Sci Rep. 2022;12(1):2752.
Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (opent nieuw venster)
Bron: Haematologica 2004;89(10):1172-8.
Hydroxyurea therapy in 49 patients with major beta-thalassemia. (opent nieuw venster)
Bron: Arch Iran Med 2009;12(3):295-7.
Recombinante erytropoëtine (afzonderlijk of in combinatie met andere middelen)
Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (opent nieuw venster)
Bron: Eur J Haematol 1996;56(5):326-8.
Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (opent nieuw venster)
Bron: J Matern Fetal Med 1999;8(1):1-7.
Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (opent nieuw venster)
Bron: Acta Haematol 2004;111(4):189-95.
Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (opent nieuw venster)
Bron: Ann Hematol 2001;80(8):492-5.
Fetal globin induction--can it cure beta thalassemia? (opent nieuw venster)
Bron: Hematology Am Soc Hematol Educ Program 2005:38-44.